- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02896270
Valproic Acid for Idiopathic Nephrotic Syndrome (VAIN)
A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome
The trial investigates the use of VPA (Valproic Acid) for the treatment of adult patients with biopsy proven idiopathic focal segmentel glomerulosclerosis (FSGS) or minimal change disease (MCD).
VPA used as an add-on to steroids might induce clinical remission in a first category of patients and potentially reduce the dose of maintenance immunosuppression required to maintain remission thereafter.
In a second category of patients VPA might allow the reduction or even cessation of immunosuppression while clinical remission is maintained.
Study Overview
Status
Intervention / Treatment
Detailed Description
Idiopathic MCD to treat diseases with a considerable associated morbidity and mortality. Current treatment options are limited, have limited efficacy and a considerable side effect profile. Recent findings in a murine model suggest that VPA treatment in an early phase of renal disease could halt or even prevent the development of proteinuria and the progression of kidney damage. VPA is a commonly used and easy available oral antiepileptic agent with a favorable side effect profile compared to the current standard of care agents for podocytopathies.
This trial investigates wether
- VPA on top of or in substitution of standard of care agents is effective in remission induction in patients with FSGS or MCD with proteinuria resistant to first line therapy with corticosteroids.
- VPA is effective in remission maintenance allowing reduction and cessation of chronic immunosuppression without relapse in patients with frequently relapsing FSGS or MCD.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Peter Janssens, MD
- Phone Number: +32 2 477 6224
- Email: Peter.Janssens@uzbrussel.be
Study Contact Backup
- Name: Nathalie Marmitte, Coordinator
- Phone Number: +32 2 477 6224
- Email: Nathalie.Marmitte@uzbrussel.be
Study Locations
-
-
-
Brussels, Belgium, 1090
- Recruiting
- University Hospital Brussels
-
Contact:
- Peter Janssens, MD
- Phone Number: +32 2 477 6224
- Email: Peter.Janssens@uzbrussel.be
-
Contact:
- Nathalie Marmitte, Coordinator
- Phone Number: +32 2 477 6224
- Email: Nathalie.Marmitte@uzbrussel.be
-
Brussels, Belgium
- Recruiting
- UVC Brugmann
-
Contact:
- Tatiana Besse-Hammer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to give informed consent
- Biopsy proven idiopathic FSGS or MCD
Organ function:
- Bilirubin/AST/ALT< 2 ULN
- PLT>100.000 10*6/L
- INR 1.5 except if on anti-vitamin K treatment
- Lipase <1.5 ULN
- Creatinine clearance >30ml/min -
Exclusion Criteria:
- Contraindication for VPA
- Secondary etiologies for FSGS or MCD
- Multiple organ transplantation
- Currently participating in another clinical trial
- Pregnant or lactating women
- Women unwilling to take efficient contraceptive measures for the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium). Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml). During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion. |
The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators.
It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In remission group induction is the proportion of patients in complete remission
Time Frame: 6 months
|
Complete remission is defined as a reduction of proteinuria to <300mg/g creatinine or < 0.3g/d and normal serum creatinine (or stable creatinine if baseline creatinine before disease onset is well documented) and serum albumin > 3.5g/dL.
|
6 months
|
In remission maintenance group is the proportion of patients able to reduce maintenance
Time Frame: 6 months
|
The proportion of patients able to reduce maintenance immunosuppression to a monotherapy of 4 mg methylprednisolone or less while remaining in complete remission
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the disease response by the proportion of subjects with partial remission
Time Frame: 6 - 12 months
|
Remission induction patients with partial remission defined as a reduction in proteinuria to 0.3-3.5g/d or 300-3500mg/g creatinine and a decrease of at least 50% from baseline proteinuria and stable serum creatinine (change in creatinine < 25%) 6 months after inclusion into the study for FSGS. Remission maintenance patients remaining in remission for at least 6 months after reduction of maintenance immunosuppression to monotherapy with 4 mg of methylprednisolone or less. |
6 - 12 months
|
Determine the extent to which standard immunosuppression can be reduced
Time Frame: 6 - 12 months
|
The proportion of "remission induction patients" attaining full or partial remission with 4mg methylprednisolone or less 6 months and 12 months after inclusion; The proportion of "remission maintenance patients" remaining in remission for at least 6 months after reduction of maintenance immunosuppression to monotherapy with 4 mg of methylprednisolone or less.
|
6 - 12 months
|
Evaluate the evolution of renal function estimated by MDRD-GFR
Time Frame: 12 months
|
Evolution of renal function estimated by CKD-EPI
|
12 months
|
Evaluate the tolerability of VPA in the setting of idiopathic podocytopathies
Time Frame: 12 months
|
Evaluation adverse events
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter Janssens, MD, University Hospital Brussels, Belgium
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease
- Nephritis
- Glomerulonephritis
- Syndrome
- Glomerulosclerosis, Focal Segmental
- Nephrotic Syndrome
- Nephrosis
- Nephrosis, Lipoid
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
Other Study ID Numbers
- UZB_20160728
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Focal Segmental Glomerulosclerosis
-
Genzyme, a Sanofi CompanyCompletedPrimary Focal Segmental GlomerulosclerosisUnited States, Brazil, Germany, Italy, Spain
-
Nanjing University School of MedicineWithdrawnFocal GlomerulosclerosisChina
-
Complexa, Inc.Medpace, Inc.; MicroConstants; Kidney Research Network, formerly NephCure Accelerating... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisUnited States
-
National Institute of Diabetes and Digestive and...Genentech, Inc.; Indiana UniversityCompletedFocal Segmental Glomerulosclerosis (FSGS)United States
-
National Institute of Diabetes and Digestive and...The Cleveland ClinicCompleted
-
Mayo ClinicUniversity Health Network, Toronto; National Institute of Diabetes and Digestive... and other collaboratorsCompletedPrimary Focal Segmental GlomerulosclerosisCanada, United States
-
National Institute of Diabetes and Digestive and...Completed
-
Mallinckrodt ARD LLCCompletedIdiopathic Focal Segmental GlomerulosclerosisUnited States, Argentina, Turkey, Peru, Australia, Chile, Mexico
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedFocal Segmental GlomerulosclerosisUnited States, Canada
-
Northwell HealthTerminatedFocal Segmental Glomerulosclerosis
Clinical Trials on Valproic Acid
-
New Mexico Cancer Care AllianceCompleted
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States
-
New Mexico Cancer Care AllianceWithdrawnChronic Myelogenous LeukemiaUnited States
-
University of Sao PauloCompletedParaparesis Spastic TropicalBrazil
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System TumorsCanada, United States
-
Northwell HealthTerminatedHealthy | Obesity | PharmacokineticsUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCCompleted
-
Nantes University HospitalCompletedProgressive Supranuclear PalsyFrance
-
Johns Hopkins UniversityNational University Hospital of SingaporeWithdrawnNasopharyngeal CarcinomaSingapore